Candel Therapeutics (CADL) EPS (Weighted Average and Diluted): 2021-2024
Historic EPS (Weighted Average and Diluted) for Candel Therapeutics (CADL) over the last 4 years, with Dec 2024 value amounting to -$1.74.
- Candel Therapeutics' EPS (Weighted Average and Diluted) fell 123.53% to -$0.38 in Q4 2023 from the same period last year, while for Dec 2023 it was -$1.30, marking a year-over-year decrease of 103.12%. This contributed to the annual value of -$1.74 for FY2024, which is 32.82% down from last year.
- As of FY2024, Candel Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.74, which was down 32.82% from -$1.31 recorded in FY2023.
- Candel Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.65 during FY2022, with a 5-year trough of -$1.91 in FY2021.
- In the last 3 years, Candel Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$1.31 in 2023 and averaged -$1.23.
- As far as peak fluctuations go, Candel Therapeutics' EPS (Weighted Average and Diluted) soared by 65.97% in 2022, and later tumbled by 101.54% in 2023.
- Candel Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$1.91 in 2021, then soared by 65.97% to -$0.65 in 2022, then tumbled by 101.54% to -$1.31 in 2023, then tumbled by 32.82% to -$1.74 in 2024.